
Fluicell Investor Relations Material
Latest events

Q1 2025
9 May, 2025

Q4 2024
21 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Fluicell
Access all reports
Fluicell is a biotech company that specializes in pioneering solutions for bioprinting and single-cell biology. Established in 2012 as a spin-off from Chalmers University of Technology in Gothenburg, Sweden, Fluicell has developed a reputation for its innovative approach to studying and manipulating individual cells with precision. The company's flagship technology, Biopixlar, is a high-resolution 3D bioprinting platform capable of constructing biological tissues at the single-cell level without the need for bioink. This technology is utilized in the development of tissue-based therapies for serious diseases lacking adequate treatments, such as type 1 diabetes, cardiovascular disease, and kidney disease.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
FLUI
Country
🇸🇪 Sweden